- Molecular NameIrinotecan
- Synonymirinotecan; Irinotecan Hcl; Irinotecan Hydrochloride; Irinotecan Hydrochloride Trihydrate; Irinotecanum [INN-Latin]
- Weight588.705
- Drugbank_IDDB00762
- ACS_NO97682-44-5
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.29
- pkaN/A
- LogD (pH=7, predicted)0.46
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)-2.42
- LogSw (predicted, AB/LogsW2.0)0.08
- Sw (mg/ml) (predicted, ACD/Labs)0.05
- No.of HBond Donors1
- No.of HBond Acceptors10
- No.of Rotatable Bonds5
- TPSA111.98
- StatusFDA approved
- AdministrationN/A
- PharmacologyA topoisomerase 1 inhibitor, which prevents DNA from unwinding. Chemically, it is a semisynthetic analogue of the natural alkaloid camptothecin.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability8.0
- Protein binding49.0
- Volume of distribution (VD)150 L/m2
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmAfter intravenous administration, irinotecan is metabolised, by carboxyesterase, in the liver to the active metabolite 7-ethyl-10-hydroxycamptothecin, SN-38 and carboxylic acid. SN-38 then undergoes conjugation, by UDP-glucuronyltransferase, to SN-38 glucuronide. Another metabolite 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamphothecin (APC) is produced by oxidative attack at the piperidine group.
- Half life10.8 h; 10.4 h for the metabolite SN-38.
- ExcretionAbout 20% of the dose is excreted in urine within 24 h, <1% as SN-38 and approx. 3 to 6% as SN-38 glucuronide. Further excretion is via bile.
- Urinary Excretion16.7
- Clerance14.8 l/h/m2
- ToxicityDiarrhoea if prolonged and over 24 h can be life threatening.
- LD50 (rat)N/A
- LD50 (mouse)N/A